India's drug controller has given a go ahead to Dr Reddys Laboratories and Russian Direct Investment Fund for the phase 2 and 3 human clinical trial for Russia's Sputnik V Covid vaccine in India. The Hyderabad-based drug maker said in a press release that this will be a multi-center and randomised controlled study, which will include safety and immunogenicity study. Earlier in September, Dr Reddys and RDIF entered into a partnership to conduct clinical trials of Sputnik V vaccine and its distribution in India. As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr.Reddys upon regulatory approval in India.